Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ABVC BioPharma, Inc. - Common Stock (NQ:ABVC)

0.8213 -0.0487 (-5.60%)
Streaming Delayed Price Updated: 3:06 PM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ABVC BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Selects Additional Vitargus Phase II Study Sites
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma's Vitreous Substitute Vitargus Presented at 14th APVRS Congress
Fremont, CA - (NewMediaWire) - December 22, 2021 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and... 
Via NewMediaWire
ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Report Updated by Zacks/SCR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Provides Vitargus Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
ABVC BioPharma Reports Second Quarter 2021 Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.